Hablemos de COVID-19

Hablemos del futuro predicible que tenemos para COVID-19. 

Referencias:

1.Schmitt, J., Wang, J. Quantitative modeling of the impact of facemasks and associated leakage on the airborne transmission of SARS-CoV-2. Sci Rep 11, 19403 (2021). https://doi.org/10.1038/s41598-021-98895-9.

2. Spang, R.P., Pieper, K. The tiny effects of respiratory masks on physiological, subjective, and behavioral measures under mental load in a randomized controlled trial. Sci Rep 11, 19601 (2021). https://doi.org/10.1038/s41598-021-99100-7.

3. Blanken, T.F., Tanis, C.C., Nauta, F.H. et al. Promoting physical distancing during COVID-19: a systematic approach to compare behavioral interventions. Sci Rep 11, 19463 (2021). https://doi.org/10.1038/s41598-021-98964-z.

4. Du, W., Iacoviello, F., Fernandez, T. et al. Microstructure analysis and image-based modelling of face masks for COVID-19 virus protection. Commun Mater 2, 69 (2021). https://doi.org/10.1038/s43246-021-00160-z.

5. Pardo, Carlos Felipe, Zapata-Bedoya, Silvana, Ramirez-Varela, Andrea, Ramirez-Corrales, Daniel, Espinosa-Oviedo, Jairo-José, Hidalgo, Darío, Rojas, Nestor, González-Uribe, Catalina, García, Juan David, & Cucunubá, Zulma M.. (2021). COVID-19 and public transport: an overview and recommendations applicable to Latin America. Infectio, 25(3), 182-188. Epub May 15, 2021.https://doi.org/10.22354/in.v25i3.944.

6. Wang, B., et al. 2021. Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians. The lancet. VOLUME 15, 100276.

7. Thomas, J, S., et al. 2021. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. NEJM. DOI: 10.1056/NEJMoa2110345

Música:

Cheel: 

https://soundcloud.com/cheel

Music promoted by @RFM - Royalty Free Music [No Copyright Music]: https://youtu.be/YPXlTYa5fYU

Hoy hablaremos de lo más relevante para COVID-19 en el mes de Agosto.

REREFENCIAS:

1. Drakos, S., Chatzantonis, G., Bietenbeck, M. et al. A cardiovascular magnetic resonance imaging-based pilot study to assess coronary microvascular disease in COVID-19 patients. Sci Rep 11, 15667 (2021). https://doi.org/10.1038/s41598-021-95277-z  (1:55 – 4.25 min)

2. Katsoularis, I., et al. 2021. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. THE LANCET. DOI:https://doi.org/10.1016/S0140-6736(21)00896-5. (5:16 – 9:37 min)

3. Petherick, A., Goldszmidt, R., Andrade, E.B. et al. A worldwide assessment of changes in adherence to COVID-19 protective behaviours and hypothesized pandemic fatigue. Nat Hum Behav (2021). https://doi.org/10.1038/s41562-021-01181-x(9:39 - 11:12 min)

4. Sankary, K.M., Sippel, J.L., Eberhart, A.C. et al. Breakthrough cases of COVID-19 in vaccinated United States Veterans with spinal cord injuries and disorders. Spinal Cord (2021). https://doi.org/10.1038/s41393-021-00690-w(11:16 -15:33 min)

5. Sanderson, K. 2021. COVID vaccines protect against Delta, but their effectiveness wanes. Nature. https://doi.org/10.1038/d41586-021-02261-8(15:34 - 16:47 min)

6. Korley, F. K. et al. 2021. Early Convalescent Plasma for High-Risk Outpatients with Covid-19. NEJM. DOI: 10.1056/NEJMoa2103784 (16:48 – 18:20 min)

7. Hammerschmidt, S.I., Bosnjak, B., Bernhardt, G. et al. Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination. Cell Mol Immunol (2021). https://doi.org/10.1038/s41423-021-00755-z(18:21 -20:31 min)

8. Koopmans., M. et al. 2021.Origins of SARS-CoV-2: window is closing for key scientific studies. Nature. 596, 482-485. doi: https://doi.org/10.1038/d41586-021-02263-6(20:31 - 23:17)

9. Barda, N., et al. 2021. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. NEJM. DOI: 10.1056/NEJMoa2110475 (23:18 – 26:50 min)

Uso de música:

Road Trip by Pyrosion https://soundcloud.com/pyrosion

Creative Commons — Attribution-ShareAlike 3.0 Unported — CC BY-SA 3.0

https://creativecommons.org/licenses/...

Música promovida por: Sound Machine Channel

https://www.youtube.com/c/soundmachin...

Hablemos un poco sobre las vacunas de RNAm respecto a lo que tenemos hoy en la evidencia, sobre su seguridad, poblaciones a vacunar y seguridad. 

1. Polack, F., et al. 2020. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. engl j med 383;27.

2. Thompson MG. Et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021 Apr 2;70(13):495-500. doi: 10.15585/mmwr.mm7013e3. PMID: 33793460.

3. Britton, A.. Et al (2021). Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks - Connecticut, December 2020-February 2021. MMWR. Morbidity and mortality weekly report, 70(11), 396–401. https://doi.org/10.15585/mmwr.mm7011e3

4. Shimabukuri, T.T. et al. 2021. Preliminary findings of mRNA Covid-19 Vaccine Safety in Pregnant persons. NEJM, April,DOI: 10.1056/NEJMoa2104983.

5. Rinott, E., Youngster, I. y Lewis, YE (2021). Reduction in COVID-19 Patients Requiring Mechanical Ventilation Following Implementation of a National COVID-19 Vaccination Program — Israel, December 2020–February 2021. MMWR. Informe semanal de morbilidad y mortalidad , 70 (9), 326-328. https://doi.org/10.15585/mmwr.mm7009e3

6. Haas, E, J. et al. 2021- Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. The Lancet, ISSN 0140-6736, https://doi.org/10.1016/S0140-6736(21)00947-8.

7. Monin,. L. et al. 2021. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. April DOI:https://doi.org/10.1016/S1470-2045(21)00213-8.

8. Baden,. L R. et al. 2020. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021; 384: 403-416. DOI: 10.1056 / NEJMoa2035389.

9. Remmel,. A. 2021. COVID vaccines and safety: what the research says. Nature, Disponible en: https://www.nature.com/articles/d41586-021-00290-x. Accesado el 04 de mayo del 2021.     

10. Tenforde MW, Olson SM, Self WH, et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021. MMWR Morb Mortal Wkly Rep. ePub: 28 April 2021. DOI: http://dx.doi.org/10.15585/mmwr.mm7018e1external.

11. Baden LR. Et al. 2021. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30. PMID: 33378609; PMCID: PMC7787219.

12. Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877. PMID: 33629336.

Link New York Times para Pfizer: https://www.nytimes.com/interactive/2020/health/pfizer-biontech-covid-19-vaccine.html

Link New York times para Moderna: 

https://www.nytimes.com/interactive/2020/health/moderna-covid-19-vaccine.html

Derechos de música: 

"Scandinavianz - Breeze" is under a Creative Commons (CC BY 3.0) license.

https://youtu.be/0GbM2rL0HCY

Music promoted by BreakingCopyright: https://youtu.be/0IkBSGqevFQ

Hablaremos un poco del contexto de lo que fue el año 2020 y lo actual respecto a este tópico que tanto causa confusión.

2.Wherry, E. J., & Masopust, D. (2016). Adaptive Immunity. Viral Pathogenesis, 57–69. doi:10.1016/b978-0-12-800964-2.00005-7 

3. Ehre, C. (2020). SARS-CoV-2 Infection of Airway Cells. New England Journal of Medicine, 383(10), 969–969. doi:10.1056/nejmicm2023328  (Imagen del SARS-CoV-2)

4. Rai P, Kumar BK, Deekshit VK, Karunasagar I, Karunasagar I. Detection technologies and recent developments in the diagnosis of COVID-19 infection. Appl Microbiol Biotechnol. 2021 Jan;105(2):441-455. doi: 10.1007/s00253-020-11061-5. Epub 2021 Jan 4. PMID: 33394144; PMCID: PMC7780074.

6. Machado, B.A.S.; Hodel, K.V.S.; Barbosa-Júnior, V.G.; Soares, M.B.P.; Badaró, R. The Main Molecular and Serological Methods for Diagnosing COVID-19: An Overview Based on the Literature. Viruses 2021, 13, 40. https://doi.org/10.3390/v13010040

7. Torretta S, Zuccotti G, Cristofaro V, Ettori J, Solimeno L, Battilocchi L, D'Onghia A, Bonsembiante A, Pignataro L, Marchisio P, Capaccio P. Diagnosis of SARS-CoV-2 by RT-PCR Using Different Sample Sources: Review of the Literature. Ear Nose Throat J. 2021 Apr;100(2_suppl):131S-138S. doi: 10.1177/0145561320953231. Epub 2020 Aug 31. PMID: 32865458; PMCID: PMC7459180.

8. Woloshin, S., et al. 2020. False negative Test for SARS-CoV-2 Infection – Challenges and Implications. N Engl J Med 2020; 383:e38.

9. Sreepadmanabh M, Sahu AK, Chande A. COVID-19: Advances in diagnostic tools, treatment strategies, and vaccine development. J Biosci. 2020;45(1):148. doi: 10.1007/s12038-020-00114-6. PMID: 33410425; PMCID: PMC7683586.

Derechos de música de fondo: 

Buddha by Kontekst https://soundcloud.com/kontekstmusic​Creative Commons — Attribution-ShareAlike 3.0 Unported — CC BY-SA 3.0 Free Download / Stream: http://bit.ly/2Pe7mBN​Music promoted by Audio Library https://youtu.be/b6jK2t3lcRs

Haremos un recorrido en la evidencia disponible hasta la fecha, de aquello que se considera secuelas de la enfermedad COVID-19 o mejor llamado "Síndrome post COVID-19".

Referencias:

1.Moreno-Pérez O, Merino E, Leon-Ramirez JM, Andres M, Ramos JM, Arenas-Jiménez J, Asensio S, Sanchez R, Ruiz-Torregrosa P, Galan I, Scholz A, Amo A, González-delaAleja P, Boix V, Gil J; COVID19-ALC research group. Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study. J Infect. 2021 Mar;82(3):378-383. doi: 10.1016/j.jinf.2021.01.004. Epub 2021 Jan 12. PMID: 33450302; PMCID: PMC7802523.

2.Cares-Marambio K, Montenegro-Jiménez Y, Torres-Castro R, Vera-Uribe R, Torralba Y, Alsina-Restoy X, Vasconcello-Castillo L, Vilaró J. Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Chron Respir Dis. 2021 Jan-Dec;18:14799731211002240. doi: 10.1177/14799731211002240. PMID: 33729021; PMCID: PMC7975482.

3.Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, Kang L, Guo L, Liu M, Zhou X, Luo J, Huang Z, Tu S, Zhao Y, Chen L, Xu D, Li Y, Li C, Peng L, Li Y, Xie W, Cui D, Shang L, Fan G, Xu J, Wang G, Wang Y, Zhong J, Wang C, Wang J, Zhang D, Cao B. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021 Jan 16;397(10270):220-232. doi: 10.1016/S0140-6736(20)32656-8. Epub 2021 Jan 8. PMID: 33428867; PMCID: PMC7833295.

4.Dennis A, Wamil M, Alberts J On behalf of COVERSCAN study investigators, et al Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study BMJ Open 2021;11:e048391. doi: 10.1136/bmjopen-2020-048391

5.Nalbandian, A., Sehgal, K., Gupta, A. et al. Post-acute COVID-19 syndrome. Nat Med (2021). https://doi.org/10.1038/s41591-021-01283-z

Créditos de música de fondo: 

Hot Coffee by Ghostrifter Official